Drug Profile

EYE 201

Alternative Names: EYE-201; MK-8748; Tiespectus

Latest Information Update: 05 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EyeBio
Class Bispecific antibodies; Eye disorder therapies; Recombinant fusion proteins
Mechanism of Action TIE-2 receptor agonists; Vascular endothelial growth factor A inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Phase I/II Age-related macular degeneration; Diabetic macular oedema; Retinal vein occlusion

27 Feb 2026 EyeBiotech plans a phase II/III for Wet-age-related-macular-degeneration (Treatment naive) (Intravitreous, Injection) in March 2026 (NCT07440225)
12 Nov 2024 Phase-I/II clinical trials in Age-related macular degeneration in Puerto Rico (Intravitreous) (NCT06664502)
12 Nov 2024 Phase-I/II clinical trials in Diabetic macular oedema in Puerto Rico (Intravitreous) (NCT06664502)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com